Automation of an Early Detection Pancreatic Cancer Test Using 5-Hydroxymethylation Profiles ClearNote Health February 2, 2026
Early detection of pancreatic cancer using 5-hydroxymethylation profiles in plasma-derived cell-free DNA ClearNote Health February 2, 2026
Evaluation of the Avantect Pancreatic Cancer Test for Identifying High-Risk Pancreatic Cysts ClearNote Health February 2, 2026
Implementation of the Avantect Pancreatic Cancer Test in Newly Diagnosed Type 2 Diabetes Patients in a Clinical Setting ClearNote Health February 2, 2026
SAFE-D Trial design: Targeted pancreatic cancer screening to evaluate stage and resectability rate shift in patients with new-onset diabetes ClearNote Health February 2, 2026
Detection of High-Risk Pancreatic Cysts Using Avantect™ Blood-Based Test ClearNote Health February 2, 2026
Cell-Free DNA Epigenomic-Based Test Is Predicted to Be Cost-Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer ClearNote Health February 2, 2026
A tumor-naïve method for estimating tumor fraction using 5-hydroxymethylation cytosine in cell–free DNA ClearNote Health February 2, 2026
5hmC-seq of mCRPC cfDNA identifies loss of AR signaling in NEPC and DNPC ClearNote Health February 2, 2026
Cell-free DNA 5-hydroxymethylcytosine Profiling for the Assessment of Colorectal Cancer Biology and Treatment Response in Blood. ClearNote Health February 2, 2026
